GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of its shingles vaccine.
{iframe}https://www.in-pharmatechnologist.com/Article/2019/04/25/GSK-ramps-up-investment-into-Shingrix-production{/iframe}